Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

Published:2017-03-22 Issue:9 Volume:44 Page:1480-1489
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Sundlöv Anna^ORCID,Sjögreen-Gleisner Katarina,Svensson Johanna,Ljungberg Michael,Olsson Tomas,Bernhardt Peter,Tennvall Jan

Funder

Cancerfonden

Vetenskapsrådet

Fru Berta Kamprads Stiftelse

Gunnar Nilssons Cancerstiftelse

Swedish Radiation Safety Authority

Jubilee Clinic Cancer Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s00259-017-3678-4/fulltext.html

Reference27 articles.

1. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26(13):2124–30. doi: 10.1200/JCO.2007.15.2553 .

2. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(17):2416–23. doi: 10.1200/JCO.2010.33.7873 .

3. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35. doi: 10.1007/s00259-011-1902-1 .

4. Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikolajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38(10):1788–97. doi: 10.1007/s00259-011-1833-x .

5. Filice A, Fraternali A, Frasoldati A, Asti M, Grassi E, Massi L, et al. Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience. J Oncol. 2012;2012:320198. doi: 10.1155/2012/320198 .

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-05

2. Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy;EJNMMI Physics;2024-08-02

3. Estimation of kidney doses from [177Lu]Lu-DOTA-TATE PRRT using single time point post-treatment SPECT/CT;EJNMMI Physics;2024-07-25

4. A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?;EJNMMI Physics;2024-07-18

5. 177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors;Clinical Nuclear Medicine;2024-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3